



PRESS RELEASE

23rd January 2014

Aurobindo Pharma receives USFDA approval for Repaglinide Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received the final approval from the US Food & Drug Administration to manufacture and market Repaglinide Tablets USP 0.5mg, 1mg and 2mg. The product is ready for launch.

Repaglinide Tablets USP 0.5mg, 1mg and 2mg are the generic equivalent of Novo Nordisk Inc's Prandin® Tablets USP 0.5mg, 1mg and 2mg and indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The market size of the product is estimated to be US\$ 274 Million for the twelve months ending November 2013 according to IMS.

Aurobindo now has a total of 189 ANDA approvals (164 Final approvals including 7 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com

Website : www.aurobindo.com

Corporate Off: WaterMark Building, Level-1

Plot No.11, Survey No. 9

Kondapur, Hitech City, Hyderabad

Reg Off: Plot No. 2, Maitrivihar

Ameerpet, Hyderabad